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Background
Despite advances in surgery and combination chemother-
apy, ovarian cancer is first in terms of death rates of
gynaecological malignancies. More than 90% of ovarian
cancers arise from surface epithelium and the serous his-
tological subtype is the most commonly diagnosed
epithelial ovarian carcinoma. Extensive seeding of the
peritoneal cavity by tumour cells is often associated with
ascites, particularly in advanced, high-grade serous carci-
nomas. Currently CA-125 is the most widely used bio-
marker in the evaluation and management of women
with epithelial ovarian cancer. However, in approximately
15% of these patients CA-125 is not indicative of disease
status or progression. Therefore, an alternative tumour
marker would be useful. Osteopontin is a secreted, integ-
rin-binding glykophosphoprotein which is overexpressed
in ovarian cancer cells and thus may serve as a serum
biomarker. By combining the data from blood and fluid
from the proximity of the tumour we might be more
likely to discover a protein biomarker secreted from the
tumour rather than deriving from another part of the
body.
Methods
We analysed twenty patients treated at the Department of
Gynaecology, Ljubljana, divided into two groups: controls
(without adnexal pathology) and patients with advanced
serous ovarian cancer (International Federation of Gyne-
cology and Obstetrics (FIGO) stage III and IV). Both
serum and free peritoneal fluid including ascites were
collected and examined. Preoperative osteopontin concen-
trations were determined using the FlowCytomix Simplex
kit (eBioscience). FlowCytomix Pro 2.4 (eBioscience) was
used for data analysis.
Results
Patients with advanced ovarian cancer had significantly
increased serum osteopontin concentration vs. controls
(p < 0.013) and increased concentration of osteopontin
in ascites vs. peritoneal fluid from control patients (p <
0.001).
Conclusions
Our preliminary results suggest that osteopontin might
represent an effective biomarker associated with
advanced serous ovarian cancer due to its elevated levels
in both serum and ascites. The potential utility of osteo-
pontin determination in monitoring women with CA-
125-negative disease is worthy of exploration. However,
larger prospective trials will be needed to assess the abil-
ity of serum osteopontin to provide diagnostic and prog-
nostic information or indications of treatment response.
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